Q32 Bio (QTTB) Non Operating Income (2017 - 2026)
Q32 Bio's quarterly Non Operating Income came in at $113000.0 in Q1 2026, down 90.56% year-on-year from $1.2 million in Q1 2025, and down 0.88% quarter-over-quarter from $114000.0 in Q4 2025.
Q32 Bio has reported Non Operating Income for 10 years, with the latest figure at $113000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income fell 90.56% year-over-year to $113000.0; the trailing twelve-month figure through Mar 2026 stood at $97000.0 (down 98.12% YoY), and the FY2025 full-year result was $1.2 million, down 94.09% from the prior year.
- Non Operating Income for Q1 2026 stood at $113000.0, down from $114000.0 in the prior quarter.
- The five-year high for Non Operating Income was $131.3 million in Q1 2022, with the low at -$6.2 million in Q3 2023.
- Average Non Operating Income over 5 years is $8.6 million, with a median of $578000.0 recorded in 2023.
- Year-over-year, Non Operating Income soared 345376.32% in 2022 and slumped 586.05% in 2023.
- Tracing QTTB's Non Operating Income over 5 years: stood at $1.5 million in 2022, then tumbled by 512.16% to -$6.0 million in 2023, then jumped by 105.97% to $358000.0 in 2024, then sank by 68.16% to $114000.0 in 2025, then retreated by 0.88% to $113000.0 in 2026.
- The last three Non Operating Income figures came in at $113000.0 (Q1 2026), $114000.0 (Q4 2025), and $188000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Q32 Bio | 162.94 Mn | 112.19 Mn | - | 113,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 113,000.00 |
| Dec 31, 2025 | 114,000.00 |
| Sep 30, 2025 | 188,000.00 |
| Jun 30, 2025 | -318,000.00 |
| Mar 31, 2025 | 1.20 Mn |
| Dec 31, 2024 | 358,000.00 |
| Sep 30, 2024 | 1.22 Mn |
| Jun 30, 2024 | 2.39 Mn |
| Mar 31, 2024 | 16.05 Mn |
| Dec 31, 2023 | -6.00 Mn |
| Sep 30, 2023 | -6.17 Mn |
| Jun 30, 2023 | 1.47 Mn |
| Mar 31, 2023 | 578,000.00 |
| Dec 31, 2022 | 1.46 Mn |
| Sep 30, 2022 | 1.27 Mn |
| Jun 30, 2022 | 474,000.00 |
| Mar 31, 2022 | 131.28 Mn |
| Dec 31, 2021 | 42,000.00 |
| Sep 30, 2021 | 53,000.00 |
| Jun 30, 2021 | 52,000.00 |
| Mar 31, 2021 | 38,000.00 |
| Dec 31, 2020 | 11,000.00 |
| Sep 30, 2020 | 41,000.00 |
| Jun 30, 2020 | 357,000.00 |
| Mar 31, 2020 | 1.16 Mn |
| Dec 31, 2019 | 1.39 Mn |
| Sep 30, 2019 | 1.66 Mn |
| Jun 30, 2019 | 1.70 Mn |
| Mar 31, 2019 | 1.27 Mn |
| Dec 31, 2018 | 1.39 Mn |
| Sep 30, 2018 | 1.49 Mn |
| Jun 30, 2018 | 996,000.00 |
| Mar 31, 2018 | 479,000.00 |
| Dec 31, 2017 | 356,306.00 |
| Sep 30, 2017 | 137,202.00 |
| Jun 30, 2017 | 35,766.00 |
| Mar 31, 2017 | -863,275.00 |